The frequency of characteristic translocations generating the fusion genes MLL-AF9 t(9;11), MLL-AF4 t(4;11), PML-RARA t(15;17), AML-ETO t(8;21) and MYH11-CBFB inv(16), are higher in patients treated with topoisomerase-II poisons, often reported for etoposide, compared to patients treated with other therapies [69,70,71]. Here, KMT2A is linked to acute myeloid leukemia.